Trial Profile
Risk factors for piperacillin/tazobactam resistance in extended-spectrum beta-lactamase (ESBL) producing organisms
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Enterobacteriaceae infections
- Focus Therapeutic Use
- 11 Jun 2018 Status changed from recruiting to completed.
- 09 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2025.
- 09 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2025.